LENSAR, Inc. (LNSR) AI Stock Analysis

LENSAR, Inc. is a commercial-stage medical device company specializing in the development and marketing of advanced femtosecond laser systems designed for treating cataracts and managing pre-existing or surgically induced corneal astigmatism. Founded in 2004 and headquartered in Orlando, Florida, the company's core offering is the LENSAR Laser System. This platform integrates proprietary technologies, advanced imaging capabilities, precise procedure planning tools, and ergonomic design features intended to enhance surgical precision, efficiency, reproducibility, and visual outcomes for ophthalmic surgery patients. As of 2026, the company operates with 150 employees.

Between FY2020 and FY2025, LENSAR delivered a revenue compound annual growth rate of 17.2%, with annual revenue increasing from $34.5M in FY2021 to $58.4M in FY2025. Annual revenue growth moderated to 9.2% in FY2025, compared to 26.9% in FY2024 and 19.2% in FY2023. Gross margin decreased from 51.8% in FY2021 to 46.4% in FY2025, while operating margin was -42.1% and net margin was -58.7% in FY2025, resulting in a net income of -$34.3M. In the trailing twelve months ended June 30, 2026, revenue stood at $60.3M with quarterly revenue growing 18.4% year-over-year, generating an operating margin of 12.9% and diluted EPS of $0.18.

As of June 30, 2026, LENSAR held $13.6M in cash and short-term investments against total debt of $2.4M, resulting in a net cash position of $11.2M. The company reported shareholders' equity of $14.9M and total assets of $69.6M, alongside a current ratio of 2.39 and a debt-to-equity ratio of 0.16. In FY2025, free cash flow was -$14.9M and operating cash flow was -$14.8M. For FY2025, capital expenditures were $83,000, while share issuance contributed $590,000, contributing to a 5-year share count increase of 140.9%.

LENSAR closed at $5.80 on October 16, 2026, giving it a market capitalization of $71.3M and an enterprise value of $76.7M. The stock trades at a trailing price-to-earnings multiple of 32.2x, which is higher than the 24.6x median of its US-listed Healthcare peers. Its price-to-sales multiple of 1.2x and enterprise value-to-revenue multiple of 1.3x trade lower than the US-listed Healthcare median price-to-sales multiple of 4.1x. Over the past year, LNSR shares fell 50.9%, underperforming the S&P 500 return of 16.8%, and the stock is down 22.9% over five years compared to an 83.0% gain for the index.

Wall Street coverage on LENSAR includes 3 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $11.33, representing a 95.4% premium over the last close of $5.80. For the fiscal year ending December 31, 2026, analysts estimate revenue of $61.3M and an EPS of -$0.05. For FY2027, the single analyst covering the period projects revenue of $72.8M, representing 18.7% revenue growth, alongside an EPS estimate of -$0.51. Over the last four quarters, the company beat EPS estimates 1 time, with the next earnings announcement scheduled for November 5, 2026.

This page is an AI-written research summary of LENSAR, Inc. (LNSR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LNSR income statement, LNSR balance sheet, LNSR key metrics, LNSR analyst forecast, LNSR chart. See the LNSR stock overview for the latest quote and news.